1 / 4

Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p =0.12

30. 20. 10. 0. CORONA - Primary Endpoint. The combined endpoint of cardiovascular death or non-fatal MI or non-fatal stroke (time to first event). Placebo. Rosuvastatin 10 mg. Percent of patients with primary endpoint. Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p =0.12. 0. 6. 12.

gavan
Download Presentation

Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p =0.12

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 30 20 10 0 CORONA - Primary Endpoint The combined endpoint of cardiovascular death or non-fatal MI or non-fatal stroke (time to first event) Placebo Rosuvastatin 10 mg Percent of patients with primary endpoint Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p=0.12 0 6 12 18 24 30 36 Months of follow-up No. at risk Placebo 2497 2315 2156 2003 1851 1431 811 Rosuvastatin 2514 2345 2207 2068 1932 1484 855 Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

  2. CORONA Atherosclerotic Events 15 Post- hoc analysis of the number fatal/non-fatal MI or stroke in the primary endpoint Placebo 12 Rosuvastatin 10 mg 9 Percent of patients with event Hazard ratio = 0.84 (95% CI 0.70 to 1.00) p = 0.05 6 3 0 0 6 12 18 24 30 36 Months of follow-up No. at risk Placebo 2497 2315 2156 2003 1851 1431 811 Rosuvastatin 2514 2345 2207 2068 1932 1484 855 Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

  3. CORONA – Secondary Endpoints Total number of hospitalizations Placebo (n=2,497) 4,074 Rosuvastatin 10 mg (n=2,514) 4,000 3,694 3,000 2,564 Number of hospitalizations 2,193 2,000 1,510 1,501 1,299 1,109 1,000 0 All cause CV cause Heart failure Non-CV cause p=0.007 p<0.001 p=0.01 Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

  4. CORONA – Side Effects and Adverse Events Tolerability and safety data Placebo Rosuvastatin [n=2497] [n=2514] no. of pts no. of pts Discontinuation of study drug1546 490 Adverse event2 302 241 Patient unwilling to continue 162 187 Other reason 82 62 1Hazard ratio 0.88; (95% CI 0.78 to 0.99; p=0.03)2Hazard ratio 0.78; (95% CI 0.66 to 0.92; p=0.004) Kjekshus et al. N Engl J Med 2007;357(22):2248-61.

More Related